Skip to main content

Pyxis Oncology, Inc.

PYXS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001782223

In the last 90 days, Pyxis Oncology, Inc. insiders filed 0 open-market purchases and 1 sale; 76 institutions reported holding it in 13F filings for Q2 2026, worth $101.1M in total; no superinvestor holds it.

Superinvestors holding PYXS, Q2 2026

See all superinvestors

No superinvestor reported holding PYXS in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of PYXS each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q1 2025

    0 superinvestors holding at quarter end

    Sold out
    HHLR Advisors (Hillhouse)
  2. Q2 2023

    1 superinvestor holding at quarter end

    Reduced
    HHLR Advisors (Hillhouse) (−27.9%)
  3. Q1 2023

    1 superinvestor holding at quarter end

    Reduced
    HHLR Advisors (Hillhouse) (−30.6%)
  4. Q4 2021

    1 superinvestor holding at quarter end

    New
    HHLR Advisors (Hillhouse)